Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma
Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow-up of Patients With Hodgkin's Lymphoma in Complete Remission for at Least 2 Years
IRCCS Azienda Ospedaliero-Universitaria di Bologna
200 participants
Nov 3, 2022
INTERVENTIONAL
Conditions
Summary
Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics: * in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).
Eligibility
Inclusion Criteria4
- hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma
- Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy
- Patients of both sexes aged ≥ 18 years at enrollment
- Signature of informed consent
Exclusion Criteria1
- Concomitant second neoplasm
Interventions
It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics: * in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage II b, III or IV, Ann Arbor Classification).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06761274